Immunovant Inc. (NASDAQ:IMVT) surged by 14.64 percent, closing at $24.82 per share ahead of its third quarter earnings report. The company is set to announce its financial and operating highlights on November 10, 2025, with a conference call to follow. In the second quarter, net loss widened by 38 percent to $120.6 million.

Traders speculate on the possibility of Immunovant Inc. (NASDAQ:IMVT) being acquired by Roivant Sciences Ltd., one of its largest shareholders. While IMVT shows promise, other AI stocks may offer higher returns with limited downside risk. For insights on a cheap AI stock and Trump tariffs, check out the free report on the best short-term AI stock.

For more stock insights, explore articles on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. This article is from Insider Monkey.

Read more at Yahoo Finance: Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results